MGF: A Literature Course on Mechano Growth Factor

This six-module course summarises what peer-reviewed papers have published about MGF (mechano growth factor). It describes models, endpoints and reported results. It does not recommend any use, protocol or quantity. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision.

Module 1: What MGF Is and How It Has Been Studied

In the biomedical literature, MGF stands for mechano growth factor. It is described as an alternatively spliced variant of the insulin-like growth factor 1 (IGF-1) gene — the transcript often labelled IGF-1Ec in humans and IGF-1Eb in rodents — expressed in muscle and other tissues in association with mechanical loading and damage. What distinguishes it from systemic IGF-1 is a different C-terminal extension, the E domain. Because that domain is unique to the splice variant, most laboratory work does not use the full-length protein at all; it uses a synthetic fragment corresponding to the E domain, referred to throughout the literature as the “MGF E peptide.”

Forms that appear in published studies

• MGF E peptide — the synthetic C-terminal domain fragment, used in cultured bone marrow stromal cells by researchers studying MEK-ERK1/2 and PI3K-Akt signalling under severe hypoxia (PMID 28927682) and in a follow-up report on cell morphology, mobility and proangiogenic capacity (PMID 29441602).
• MGF-19E peptide — a designated E-peptide construct applied to MC3T3-E1 osteoblast-like cells and a bone defect model in a 2020 report (PMID 32339623).
• MGF in mechanical-loading contexts — studied as a mechanically coupled signal in a periodontal regeneration model (PMID 38193124) and in tenocyte migration work (PMID 25847391).

An acronym that collides with unrelated fields

Anyone searching databases for “MGF” will encounter two large literatures that have nothing to do with growth factors. In virology, MGF denotes the multigene families of African swine fever virus: separate papers have characterised MGF 360-2L in transcriptomic analyses of host antiviral immunity (PMID 41012121), the MGF 110-11L gene in viral replication and virulence (PMID 37112759), and MGF 505-3R in relation to innate immune signalling (PMID 41673114). In materials science, MgF₂ is magnesium fluoride, appearing in work on coatings for bioresorbable magnesium alloy stents (PMID 40955374), a PLLA/MgF₂ coating applied by ultrasonic atomisation spraying (PMID 36676415), a mechanoluminescent MgF₂:Mn²⁺ material (PMID 36546135) and MgF₂ dehydrofluorination catalysts (PMID 35530601). None of those papers describe a peptide.

Limits of the evidence in Module 1

The definitional literature is descriptive. Peptide constructs described as “MGF E peptide” differ between laboratories in length, sequence boundaries, purity and solvent, and the published reports do not establish that material sold under the name “MGF” outside research settings matches any construct used in these studies. Acronym overlap also means that database hit counts for “MGF” substantially overstate the size of the peptide literature.

Module 2: Mechanism as Described in the Literature

Mechanistic papers on MGF E peptide have converged on a small set of intracellular signalling cascades, examined mostly in cultured cells.

ERK1/2 and Akt signalling

In bone marrow stromal cells (BMSCs) cultured under severe hypoxia, researchers reported that MGF E peptide pretreatment acted through MEK-ERK1/2 and PI3K-Akt pathways in relation to proliferation and osteogenic differentiation endpoints (PMID 28927682). A subsequent study from the same research area used pathway inhibition to test necessity, and reported that ERK1/2 and Akt phosphorylation were essential for the effects of MGF E peptide on BMSC morphology and mobility but not for proangiogenic capacity under severe hypoxia (PMID 29441602). That dissociation matters: it indicates that different downstream readouts in the same cell type did not depend on the same kinases.

FAK-ERK1/2 and matrix metalloproteinase activity

In tendon cells, the study reported that MGF enhanced tenocyte invasion through MMP-2 activity via the FAK-ERK1/2 pathway (PMID 25847391). Focal adhesion kinase links cell-matrix adhesion to migratory signalling, and MMP-2 is a gelatinase that degrades extracellular matrix, so the proposed mechanism in that paper is adhesion-coupled proteolysis rather than simple growth stimulation.

Mechanical coupling

A 2024 report framed MGF as part of a mechanochemical coupling mechanism in periodontal regeneration, connecting applied mechanical signals to tissue-level outcomes (PMID 38193124). This framing reflects the origin of the name: the splice variant was identified in the context of mechanical stimulus rather than as a circulating endocrine hormone.

Limits of the evidence in Module 2

Pathway work of this kind is performed in defined culture conditions with pharmacological inhibitors. Inhibitor specificity is imperfect, hypoxic culture is an artificial stressor, and demonstrating that a kinase is required in a dish does not establish which receptor MGF E peptide engages, whether that engagement occurs at physiological concentrations, or how the peptide behaves in an intact organism.

Module 3: Reported Outcomes by Study

The table below summarises what each verified peptide-related paper examined and what it reported. No quantities are listed because the verified sources summarised here do not supply usable dosing information for any non-laboratory context.

Limits of the evidence in Module 3

Every entry above is preclinical. Four of the five are dominated by cell culture endpoints, and the tissue-level work uses localised defect or regeneration models where the peptide is presented at an injury site rather than administered systemically. Cell proliferation and mineralisation assays are surrogate measures; they are not clinical outcomes such as fracture union time, tendon rupture recurrence or function scores. None of these reports constitutes evidence of benefit in humans, and no randomised controlled human trial appears among them.

Module 4: MGF Side Effects: What Studies Report

The honest summary is that the verified literature reviewed here does not contain published adverse-event data for MGF in people. The bone cell and defect-healing report described proliferation, differentiation, mineralisation and healing endpoints (PMID 32339623), and the two BMSC papers described proliferation, differentiation, morphology, mobility and proangiogenic endpoints under hypoxia (PMID 28927682, PMID 29441602). Those are efficacy-style laboratory readouts. They are not safety pharmacology, toxicology, immunogenicity or organ-histopathology studies, and no adverse event frequency tables appear in them.

Mechanistic observations that are sometimes discussed as theoretical concerns

Two published observations are worth stating precisely, without extrapolating beyond them. First, the tenocyte study reported that MGF enhanced cell invasion through MMP-2 activity (PMID 25847391); matrix metalloproteinase activation is a matrix-remodelling process, and that paper examined it as a wound-repair mechanism rather than as a harm. Second, MGF is an IGF-1 splice product, and the cited papers reported proliferative effects in cultured cells (PMID 28927682, PMID 32339623); the studies did not evaluate whether such proliferative signalling has consequences in non-target tissues over time. Anything beyond those statements — including claims about specific injection-site reactions, hormonal effects or long-term risk — would not be supported by the sources listed here.

Limits of the evidence in Module 4

Absence of reported adverse events in cell-culture and defect-model papers is not evidence of safety. It reflects study design: these experiments were not built to detect harm. No dose-ranging toxicity study, no immunogenicity assessment and no human tolerability data appear in the verified set, so the safety profile of MGF in humans is best described as uncharacterised in this literature.

Module 5: Pharmacokinetics Where Data Exist

Pharmacokinetic characterisation answers how much of a compound reaches circulation, how quickly it is cleared, and what tissues it distributes to. Among the verified papers, none reports plasma concentration curves, half-life, bioavailability, volume of distribution or clearance for MGF or any E peptide construct. The BMSC studies used pretreatment of cultured cells (PMID 28927682, PMID 29441602), a design in which concentration in the culture medium is set by the experimenter and systemic kinetics do not apply.

Where tissue-level work exists, it is framed around local delivery at a defect or regeneration site: the bone study assessed defect healing (PMID 32339623) and the periodontal study assessed regeneration under mechanochemical coupling (PMID 38193124). Local presentation of a peptide within a scaffold or at a wound site is a different pharmacological situation from systemic exposure, and the reports do not translate between the two.

Limits of the evidence in Module 5

General peptide chemistry predicts that short unmodified peptides are subject to rapid proteolysis and negligible oral absorption, but prediction is not measurement. Because no verified source measured these parameters for MGF, no half-life figure, no exposure estimate and no administration schedule can be stated for it from this literature.

Module 6: Regulatory Status, Stated Factually

Approved products

There is no United States Food and Drug Administration-approved drug product whose active ingredient is mechano growth factor or an MGF E peptide, and no European Medicines Agency marketing authorisation for such a product. That means no regulator has reviewed manufacturing, labelling, dosing or safety data for a finished MGF medicine.

Research-use-only status

Material distributed under the name MGF in the chemical supply market is typically labelled “research use only” (RUO) or “not for human consumption.” RUO labelling is a regulatory category for laboratory reagents: such products are not manufactured under the controls required for human medicines, are not subject to the same identity, sterility or endotoxin verification, and are not authorised for administration to people.

Compounding

Under sections 503A and 503B of the US Federal Food, Drug, and Cosmetic Act, a compounder may generally use a bulk drug substance only if it is the subject of a USP or NF monograph, is a component of an FDA-approved drug, or appears on an FDA bulk drug substances list. Peptides without an approved product, monograph or listing do not meet those criteria, and FDA has publicly categorised a number of peptide substances as raising safety concerns for compounding.

Sport

The World Anti-Doping Agency Prohibited List includes growth factors affecting muscle, tendon or ligament protein synthesis under its growth factors and growth factor modulators category, and mechano growth factors are named within that class. Athletes subject to anti-doping rules are therefore governed by that listing regardless of a substance’s commercial availability.

This section describes publicly stated regulatory positions for educational purposes and is not legal advice; rules differ by country and change over time.

Limits of the evidence in Module 6

Regulatory status is a statement about administrative review, not about biology. A compound can be unapproved and still be actively studied, and it can be widely sold as a reagent while remaining unevaluated in humans. Readers comparing jurisdictions should consult primary regulatory texts, since national rules vary.

What the Studies Did Not Test

• Humans. None of the verified MGF papers was a clinical trial; the endpoints were cultured cells and animal or tissue models (PMID 32339623, PMID 38193124).
• Muscle hypertrophy or athletic performance. The verified reports examined osteoblast-like cells, BMSCs, tenocytes and periodontal tissue — not strength, lean mass or recovery outcomes in people (PMID 28927682, PMID 25847391).
• Dosing regimens. No verified source established an administration schedule, route or quantity applicable outside a laboratory.
• Long-term safety. No chronic toxicology, carcinogenicity or immunogenicity data appear in the verified set.
• Product identity. No verified source analysed the purity or sequence of commercially distributed material labelled “MGF.”
• Comparative effectiveness. No verified source compared MGF with an approved therapy for bone, tendon or periodontal repair.

Read this way, the MGF literature is a mechanistic story about an IGF-1 splice variant and its E domain, examined mainly in cells under controlled conditions. It is not a clinical evidence base, and the papers themselves do not claim to be one.

References

• MGF-19E peptide promoted proliferation, differentiation and mineralization of MC3T3-E1 cell and promoted bone defect healing (Gene, 2020)
• MGF E peptide pretreatment improves the proliferation and osteogenic differentiation of BMSCs via MEK-ERK1/2 and PI3K-Akt pathway under severe hypoxia (Life Sciences, 2017)
• ERK1/2 and Akt phosphorylation were essential for MGF E peptide regulating cell morphology and mobility but not proangiogenic capacity of BMSCs under severe hypoxia (Cell Biochemistry and Function, 2018)
• MGF enhances tenocyte invasion through MMP-2 activity via the FAK-ERK1/2 pathway (Wound Repair and Regeneration, 2015)
• Mechanochemical coupling of MGF mediates periodontal regeneration (Bioengineering & Translational Medicine, 2024)
• African Swine Fever Virus MGF 360-2L Disrupts Host Antiviral Immunity Based on Transcriptomic Analysis (Vaccines, 2025)
• Involvement of the MGF 110-11L Gene in the African Swine Fever Replication and Virulence (Vaccines, 2023)
• African swine fever virus-encoded protein MGF 505-3R impairs innate immunity via ubiquitin-mediated degradation of MyD88 (Communications Biology, 2026)
• A hierarchical MgF2/polyurethane/pitavastatin coating alleviates degradation and enhances endothelialization of bioresorbable magnesium alloy stents (Bioactive Materials, 2025)
• A Novel PLLA/MgF2 Coating on Mg Alloy by Ultrasonic Atomization Spraying for Controlling Degradation and Improving Biocompatibility (Materials, 2023)
• MgF2:Mn2+: novel material with mechanically-induced luminescence (Science Bulletin, 2022)
• Rational design of MgF2 catalysts with long-term stability for the dehydrofluorination of 1,1-difluoroethane (HFC-152a) (RSC Advances, 2019)